PainReform Ltd. (PRFX)

NASDAQ: PRFX · Real-Time Price · USD
2.300
+0.060 (2.68%)
Apr 23, 2025, 4:00 PM EDT - Market closed
2.68%
Market Cap 3.92M
Revenue (ttm) n/a
Net Income (ttm) -14.59M
Shares Out 1.71M
EPS (ttm) -32.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,964
Open 2.340
Previous Close 2.240
Day's Range 2.280 - 2.360
52-Week Range 0.432 - 16.630
Beta 0.72
Analysts Hold
Price Target n/a
Earnings Date May 14, 2025

About PRFX

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated ... [Read more]

Sector Healthcare
IPO Date Sep 1, 2020
Employees 6
Stock Exchange NASDAQ
Ticker Symbol PRFX
Full Company Profile

Financial Performance

Financial Statements

News

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, tod...

13 days ago - GlobeNewsWire

PainReform Provides Year-End Business Update

TEL AVIV, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a specialty pharmaceutical company focused on the reformulation of established ther...

16 days ago - GlobeNewsWire

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Acquisition Positions PainRef...

7 weeks ago - GlobeNewsWire

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains comm...

2 months ago - GlobeNewsWire

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es...

4 months ago - GlobeNewsWire

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es...

5 months ago - GlobeNewsWire

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es...

5 months ago - GlobeNewsWire

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain M...

8 months ago - GlobeNewsWire

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e...

8 months ago - GlobeNewsWire

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es...

8 months ago - GlobeNewsWire

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) --   PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of ...

9 months ago - GlobeNewsWire

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

New process expected to significantly bolster future commercialization efforts New process expected to significantly bolster future commercialization efforts

9 months ago - GlobeNewsWire

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of est...

11 months ago - GlobeNewsWire

PainReform Provides Business Update for the First Quarter of 2024

Reaches 50% e nrollment in the s econd p art of its Phase 3 c linical t rial of PRF-110 in b unionectomy

1 year ago - GlobeNewsWire

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

TEL AVIV, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of est...

1 year ago - GlobeNewsWire

PainReform Announces Closing of $4 Million Public Offering

TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of e...

1 year ago - GlobeNewsWire

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

TEL AVIV, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e...

1 year ago - GlobeNewsWire

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

TEL AVIV, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e...

1 year ago - GlobeNewsWire

PainReform to Present at the Microcap Conference in Atlantic City

Tel Aviv, Israel--(Newsfile Corp. - January 22, 2024) - PainReform Ltd. (NASDAQ: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation o...

1 year ago - Newsfile Corp

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading PRF-110 demonstrated superior formulation properties with respect to surface-tissue spreading

1 year ago - GlobeNewsWire

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

TEL AVIV, Israel, Dec. 26, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e...

1 year ago - GlobeNewsWire

PainReform Provides Business Update for the Third Quarter of 2023

Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy Reports enrollment of first patients for the second part of Phase 3 clinical trial in bunionectomy

1 year ago - GlobeNewsWire

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 TEL AVIV, Israel, Sept. 11, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd.

1 year ago - GlobeNewsWire

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Professor Eli Hazum to Share Positi...

1 year ago - GlobeNewsWire

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

TEL AVIV, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of e...

1 year ago - GlobeNewsWire